急性呼吸窘迫综合征
一氧化氮
医学
重症监护医学
肺动脉高压
急性呼吸窘迫
肺水肿
2019年冠状病毒病(COVID-19)
肺
内科学
疾病
传染病(医学专业)
作者
Brian Strickland,N. Stuart Harris
出处
期刊:Nitric Oxide
[Elsevier BV]
日期:2024-04-05
卷期号:146: 58-63
被引量:1
标识
DOI:10.1016/j.niox.2024.04.003
摘要
Nitric oxide was first identified as a novel and effective treatment for persistent pulmonary hypertension of the newborn (PPHN), and has since been found to be efficacious in treating acute respiratory distress syndrome (ARDS) and pulmonary hypertension. Physicians and researchers have also found it shows promise in resource-constrained settings, both within and outside of the hospital, such as in high altitude pulmonary edema (HAPE) and COVID-19. The treatment has been well tolerated in these settings, and is both efficacious and versatile when studied across a variety of clinical environments. Advancements in inhaled nitric oxide continue, and the gas is worthy of investigation as physicians contend with new respiratory and cardiovascular illnesses, as well as unforeseen logistical challenges.
科研通智能强力驱动
Strongly Powered by AbleSci AI